SCHEMBL2622211

SCHEMBL2622211

CC(C)(C)Nc1nccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.50
RAB9A P51151 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
FDPS P14324 1/20 0.47
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
ATM Q13315 1/20 0.46
PLAU P00749 2/20 0.46
F12 P00748 1/20 0.46
NCF1 P14598 1/20 0.46
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46
BACE1 P56817 1/20 0.46
CCNE2 O96020 3/20 0.45
CCNE1 P24864 3/20 0.45
CDK2 P24941 3/20 0.45
CDK4 P11802 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4479184 0.79 CYP2A6 (0.55) CYP2A6RAB9AMEN1KMT2AFDPS
SCHEMBL6175758 0.78 EGFR (0.56) CYP2A6RAB9AFDPSCYP3A4TSHR
SCHEMBL34467229 0.78 EGFR (0.56) CYP2A6RAB9AFDPSCYP3A4TSHR
SCHEMBL12933395 0.77 CYP2A6 (0.46) CYP2A6RAB9AFDPSCYP3A4TSHR
SCHEMBL270468 0.77 EGFR (0.42) CYP2A6RAB9AMEN1KMT2AFDPS
SCHEMBL20319082 0.76 MAPT (0.47) RAB9AMEN1KMT2ACYP3A4TSHR
SCHEMBL12376733 0.76 KDM4E (0.48) CYP2A6RAB9AFDPSCYP3A4TSHR
SCHEMBL6702643 0.75 PRKCH (0.45) CYP2A6FDPSCYP3A4TSHRCYP2C19
SCHEMBL24170548 0.75 FDPS (0.51) CYP2A6RAB9AKMT2AFDPSCYP3A4
SCHEMBL1133566 0.75 FDPS (0.56) CYP2A6RAB9AFDPSCYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112390755-B Heteroaryl method for amine 中国科学院理化技术研究所 2024-08-02 CN claimed
US-20130274278-A1 IAP INHIBITORS TETRALOGIC PHARM CORP (US) 2013-10-17 US disclosed
US-20130274278-A1 IAP INHIBITORS TETRALOGIC PHARM CORP (US) 2013-10-17 US disclosed
US-8481495-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-07-09 US disclosed
US-8481495-B2 IAP inhibitors TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-07-09 US disclosed
US-20120094917-A1 IAP INHIBITORS TETRALOGIC PHARMACEUTICALS CORP (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274278-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 CYP2A6 4324/4885RAB9A 1074/4885MEN1 2419/4885
US-20120094917-A1 IAP INHIBITORS XIAP, IAPP, BIRC5 CYP2A6 4324/4885RAB9A 1074/4885MEN1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.